Background Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI. This is a retrospective study that analyses a nosocomial outbreak of RSV infections in the Neonatology clinic of the University Hospital of Obstetrics and Gynecology, Sofia, 2019. Methods Two groups of infants without contact between them were diagnosed with RSV-infection: 14 infants were treated in the Department for healthy newborns – Group 1, and 7 preterm infants were treated in the Neonatal Intensive Care Unit (NICU) – Group 2. The detection of RSV was performed using Real-Time PCR in nasal/throat swabs. Results Respiratory symptoms occurred 2–5 days after discharge in 14 of 148 healthy term infants born February 5 to 18, 2019; 12 babies were re-hospitalized with LRTI and recovered in a few days. RSV-PCR was positive in 6 infants, while in the others, RSV etiology was suggested, due to similar symptoms and contact between them. The first NICU patient with RSV-LRTI was one of the 26 gestational weeks (GW) twins, who had severe BPD. The other twin was always discharged home without LRTI-symptoms. In the period February 19 to March 15, 2019, 26 premature babies born at 26–34 GW, were tested for RSV (33 nasal/throat swabs). They received a first or subsequent palivizumab injection. We identified 11 positive samples in 7 of the babies. Despite the clinical recovery, the second RSV-PCR remained positive in 4 babies. Six of the 7 NICU patients had symptoms of LRTI, and two of them needed mechanical ventilation. Six babies were discharged home after stabilization, one was transferred to the Pediatric department for further treatment of BPD and later discharged too. Conclusions This was the most serious outbreak of RSV infections in neonates since the RSV-PCR diagnostic in Bulgaria was introduced. The course of RSV-LRTI was severe in extremely preterm patients with underlying BPD. So, routine in-hospital RSV-prophylaxis with palivizumab should be considered for infants at the highest risk.
Background: Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI. We report retrospectively a nosocomial outbreak of RSV-infections in the Neonatology of the University O&G hospital, Sofia. Methods: Two groups of infants without contact between them were diagnosed with RSV-infection: 14 infants who were treated in the Department for healthy newborns, and 7 preterm infants, treated in the NICU. The detection of RSV was performed using Real-Time PCR in nasal/throat swabs.Results: Respiratory symptoms occurred 2-5 days after discharge in 14 of 148 healthy term infants born from 5 to 18 February 2019; 12 babies were re-hospitalized with LRTI and recovered in a few days. In 6 infants the RSV-PCR was positive, in the others, RSV etiology was suggested due to similar symptoms and contact between them.The first NICU-patient with RSV-LRTI was a 26 gestational weeks (GW) twin with BPD. From 19 February to 15 March 26 babies, 26-34 GW at birth were tested for RSV (33 nasal/throat swabs). They received a first or subsequent palivisumab-injection. We identified 11 positive samples in 7 of the babies. Six of them were with symptoms of LRTI, two needed mechanical ventilation. In 4 babies despite the recovery, the second RSV-PCR remained positive. After stabilization 6 babies were discharged home, one was transferred to the Paediatric department for further treatment of BPD. Conclusions: The reported outbreak of RSV-infections in neonates was the most serious since the RSV-PCR diagnostic in Bulgaria was introduced. The course of RSV-LRTI was severe in extremely preterm newborns with underlying BPD. So routine in-hospital RSV-prophylaxis with palivizumab should be considered for infants at the highest risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.